Trial Profile

The Heart Institute of Japan Candesartan Randomized trial for Evaluation in Coronary Artery Disease

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Candesartan cilexetil (Primary) ; Antihypertensives
Indications Cardiovascular disorders; Coronary artery disease; Essential hypertension; Hypertension
Focus Therapeutic Use
Acronyms HIJ-CREATE

Most Recent Events

01 Sep 2020 Results of this post-hoc analysis presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
31 May 2020 Results of post-hoc analysis assessing impact of age on clinical outcomes of antihypertensive therapy in patients with hypertension and CAD, published in the Journal of Clinical Hypertension (Greenwich).
20 Nov 2013 Results of an analysis in patients with chronic kidney disease presented at the 86th Annual Scientific Sessions of the American Heart Association.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com